Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Sponsors

Lead Sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.

Source Sanwa Kagaku Kenkyusho Co., Ltd.
Brief Summary

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Overall Status Completed
Phase Phase 3
Study Type Interventional
Condition
Intervention

Intervention Type: Drug

Intervention Name: Miglitol

Eligibility

Criteria:

Inclusion Criteria: - Type 2 diabetic patients treated with Biguanide - Criteria for postprandial plasma glucose and HbA1c are met Exclusion Criteria: - Type 1 diabetes - Patients treated with other antidiabetic drugs or Insulin

Gender:

All

Minimum Age:

20 Years

Maximum Age:

69 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Clinical Study Group, Clinical Development Dept. Study Director Sanwa Kagaku Kenkyusho Co., Ltd.
Location
Facility:
| Aichi, Japan
| Chiba, Japan
| Fukuoka, Japan
| Gifu, Japan
| Gunma, Japan
| Hokkaido, Japan
| Ibaragi, Japan
| Kanagawa, Japan
| Kumamoto, Japan
| Miyazaki, Japan
| Osaka, Japan
| Saitama, Japan
| Tochigi, Japan
Location Countries

Japan

Verification Date

2008-10-01

Keywords
Has Expanded Access No
Condition Browse
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Double

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News